Financial News

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%. Over five years, FHLC has returned 15% against about 80% for the S&P 500. If you bought FHLC for cheap sector diversification, fine. If you bought it expecting healthcare to keep pace with ... If You Hold This Healthcare ETF, You’re Losing Big

Tectonic Therapeutics (TECX) and TX45 for PH-HFpEF: Phase 1b results, risks, and the pivotal Phase 2 APEX catalyst due YE26—read the analysis now.

Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.

I present my top dividend growth picks for each of the 11 GICS sectors, emphasizing discounted valuations and safe, growing dividends.

Eli Lilly’s obesity/diabetes outlook: Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges to the Biden-era program.

Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. See why LLY stock is a Buy.

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

U.S. Supreme Court declined to hear Eli Lilly's appeal in a major whistleblower case tied to Medicaid rebates. The decision leaves in place a significant judgment related to allegations the company underpaid rebates to the government program. The ruling highlights legal and compliance risks around how pharmaceutical companies interact with U.S. government healthcare programs. Eli Lilly (NYSE:LLY) faces this legal setback with its stock at $1,004.92, after a gain of 3.9% over the past week...

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State St

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

Trump said he is increasing the number of products on the platform by nearly seven times, adding more than 600 generic drugs to the site.

Strong drug sales continue to drive growth, but expectations are climbing

Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president of Lilly Research Laboratories, will take part in a fireside chat at 1:30 p.m., Eastern time.

Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the RBC Capital Markets Global Healthcare Conference in New York, NY. The company’s presentation will be on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. To access the live and arch

Eli Lilly (LLY) fits the GARP strategy with strong growth, a 9/10 profitability rating, and a reasonable valuation. Learn how this pharma giant balances high earnings growth with an affordable price.

The U.S. Supreme Court declined on Monday to hear a challenge by drugmaker Eli Lilly to a Civil War-era whistleblower law that has recovered billions of dollars by allowing private individuals to...

https://www.bloomberg.com/news/articles/2026-05-18/lilly-rebuffed-by-supreme-court-on-194-million-medicaid-award

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Alex Zhavaronkov, the Founder, CEO and CBO of Insilico Medicine, joins Squawk Box Asia to discuss the usage of AI in the pharmaceutical industry, and the company's business strategy and outlook.

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, while also committing an additional US$4.50 billion to expand its Indiana manufacturing network for obesity and genetic medicines. The combination of durable weight maintenance data for Foundayo and Zepbound and large-scale production expansion underscores how central obesity treatments have become...

Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 10 years. On May 5, Emily Field from Barclays lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350 and maintained an Overweight rating following the first-quarter results. In a research note, the analyst […]